KemPharm is a biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. Its primary efforts include the development of safer, abuse resistant opioid pain relievers. KemPharm’s drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. The Company uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.
Type
Public
HQ
Kissimmee, US
Founded
2006
Size (employees)
32 (est)
KemPharm was founded in 2006 and is headquartered in Kissimmee, US
Report incorrect company information

KemPharm Office Locations

KemPharm has an office in Kissimmee
Kissimmee, US (HQ)
1180 Celebration Blvd
Show all (1)
Report incorrect company information

KemPharm Financials and Metrics

KemPharm Financials

USD

Net income (FY, 2016)

(16.5 m)

EBIT (FY, 2016)

(37.5 m)

Market capitalization (18-Apr-2018)

91.1 m
KemPharm's current market capitalization is $91.1 m.
USDFY, 2015FY, 2016

General and administrative expense

2.6 m14 m

R&D expense

4.7 m20.5 m

Operating expense total

7.3 m34.5 m

EBIT

(7.3 m)(37.5 m)
Annual
USDFY, 2015FY, 2016

Cash

32.3 m16.8 m

Inventories

2.8 m489 k

Current Assets

54.1 m74.4 m

PP&E

403 k2 m
Quarterly
USDQ3, 2017

Inventories

1.4 m

Accounts Payable

6.4 m
Annual
USDFY, 2015FY, 2016

Net Income

(54.7 m)(16.5 m)

Depreciation and Amortization

84 k175 k

Inventories

(1.2 m)(15.9 m)

Accounts Payable

1.3 m1.1 m
Quarterly
USDQ1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Inventories

1.4 m

Accounts Payable

4 m4.9 m4.2 m5.4 m5.6 m4.6 m6.3 m6.4 m
Show all financial metrics
Report incorrect company information